All In Biotech

Drug Trial Radar · NCT06292780

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Aug 7, 2024

Primary completion

Aug 20, 2028

Study completion Feb 20, 2035

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists of 2 phases (Phase 1 and Phase 2): * In Phase 1, linvoseltamab will be given to a small number of participants to study the side effects of the study drug and to determine the recommended doses of the study drug to be given to participants in Phase 2. * In Phase 2, linvoseltamab will be given to more participants to continue to assess the side effects of the study drug and to evaluate the ability of linvoseltamab to treat AL amyloidosis. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab have improvement in the abnormal proteins that cause organ problems and for how long * How many participants treated with linvoseltamab have improvement in the heart or kidney and for how long * What the right dosing regimen is for linvoseltamab * What side effects may happen from taking linvoseltamab * How much linvoseltamab is in the blood at different times * Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects)

Conditions

  • Relapsed/Refractory Systemic Light Chain Amyloidosis

Interventions

  • LinvoseltamabDrug

    anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicity (DLTs)Time frame: Up to 28 Days
  2. Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)Time frame: Up to 3 years

Locations

24 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Colorado Blood Cancer Institute/SCRI

    Denver, Colorado · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • National and Kapodistrian University of Athens

    Athens, Greece · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul St. Mary's Hospital - The Catholic University of Korea

    Seoul, South Korea · Recruiting

  • Universität de Barcelona- Institut d' Investigacions Biomediques August Pi i Sunyer (IDIBAPS)

    Barcelona, Spain · Recruiting

  • University Hospital La Fe

    Valencia, Spain · Recruiting

  • Hospital Universitari Son Espases

    Palma, Balearic Islands, Spain · Recruiting

  • Clinica Universidad de Navarra - Pamplona

    Pamplona, Navarre, Spain · Recruiting

  • Hospital de Cabuenes

    Gijón, Principality of Asturias, Spain · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • Tri-Service General Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Municipal Wan Fang Hospital

    Taipei, Taiwan · Recruiting

  • University College London Hospitals

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Withdrawn

  • Manchester Royal Infirmary

    Manchester, Greater Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.